Evaluating the effects of inhaled corticosteroids in children with asthma
Evaluate the Therapeutic Effect of Inhaled Corticosteroid in Asthmatic Children
This study is trying to see how well inhaled corticosteroids work for children with asthma and what factors might affect their response to the treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 5 Years to 18 Years |
| Sex | All |
| Sponsor | National Taiwan University Hospital Academic / other |
| Locations | 1 site (Taipei) |
| Trial ID | NCT03487809 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the therapeutic effects of inhaled corticosteroids (ICS) in children diagnosed with asthma, focusing on the clinical and genetic factors that may influence medication effectiveness. Despite ICS being the first-line treatment for asthma, there is significant variability in patient responses, with a notable percentage classified as non-responders. The study will explore various factors, including genetic variability, that could contribute to this variability in treatment response. By understanding these factors, the study seeks to improve asthma management in pediatric patients.
Who should consider this trial
Good fit: Ideal candidates for this study are children diagnosed with asthma by specialists, particularly those whose symptoms began before the age of 10.
Not a fit: Patients with cancer, major immunological diseases, or those who have recently used inhaled corticosteroids or oral steroids may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized asthma treatment strategies for children, enhancing medication effectiveness.
How similar studies have performed: Other studies have indicated variability in response to asthma medications, but this specific approach focusing on genetic factors in children is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed by asthma specialists, the age of onset was under 10 years old Exclusion Criteria: * Children with cancer, major immunological diseases, such as systemic lupus erythematosus (SLE) or Henoch-Schonlein purpura (HSP), rare hereditary diseases, or under severe infection. * Children who received ICS or oral steroid in recent 4 weeks
Where this trial is running
Taipei
- Ntuh — Taipei, Taiwan (Recruiting)
Study contacts
- Principal investigator: Yungling Lee, Professor — Ntuh
- Study coordinator: Yungling Lee, Professor
- Email: leolee@ibms.sinica.edu.tw
- Phone: 886-2-26523013
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.